623 related articles for article (PubMed ID: 22370319)
1. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
[TBL] [Abstract][Full Text] [Related]
2. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
3. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Song Y; Yang L; Zhou A; Chi Y; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
5. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Lehmann J; Retz M; Steiner G; Albers P; Jaeger E; Knuth A; Lippert C; Koser M; Stockamp K; Otto C; Melchior H; Fassmann C; Potratz C; Loch T; Derigs HG; Becker T; Kälble T; Piechota HJ; Hertle L; Weinknecht S; Weissbach L; Al-Mwalad M; Hamza A; Henss H; Brkovic D; Pomer S; Roloff J; Walz P; Muschter R; Tunn U; Winter E; Bub P; Kaldenbach U; Roth S; Brauers A; Jakse G; Richter AE; Wirth M; Hartlapp J; Van Ahlen H; Stöckle M
Urologe A; 2003 Aug; 42(8):1074-86. PubMed ID: 14513232
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
[TBL] [Abstract][Full Text] [Related]
9. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
10. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
Cheng T
Curr Opin Support Palliat Care; 2008 Sep; 2(3):153-60. PubMed ID: 18685414
[TBL] [Abstract][Full Text] [Related]
12. Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.
Yamamoto K; Sasano T; Tsuji D; Ishizuka Y; Tokou U; Nakamichi H; Yoneda T; Shiokawa M; Yabe K
Ann Pharmacother; 2019 Jul; 53(7):690-696. PubMed ID: 30734587
[TBL] [Abstract][Full Text] [Related]
13. Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Wang Y; Xu L; Meng X; Qin Z; Wang Y; Chen C; Wang Y; Zhou X; Zhang Q; Xia J; Song N
Cell Physiol Biochem; 2018; 50(1):1-14. PubMed ID: 30293075
[TBL] [Abstract][Full Text] [Related]
14. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
[TBL] [Abstract][Full Text] [Related]
16. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Ecke TH; Bartel P; Koch S; Ruttloff J; Theissig F
Oncol Rep; 2006 Dec; 16(6):1381-8. PubMed ID: 17089065
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
[TBL] [Abstract][Full Text] [Related]
20. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
